ZA964682B - Methods of inhibiting melanoma. - Google Patents

Methods of inhibiting melanoma.

Info

Publication number
ZA964682B
ZA964682B ZA9604682A ZA964682A ZA964682B ZA 964682 B ZA964682 B ZA 964682B ZA 9604682 A ZA9604682 A ZA 9604682A ZA 964682 A ZA964682 A ZA 964682A ZA 964682 B ZA964682 B ZA 964682B
Authority
ZA
South Africa
Prior art keywords
methods
inhibiting melanoma
melanoma
inhibiting
Prior art date
Application number
ZA9604682A
Other languages
English (en)
Inventor
Robert Alan Swift
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of ZA964682B publication Critical patent/ZA964682B/xx

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4151,2-Diazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/38Heterocyclic compounds having sulfur as a ring hetero atom
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4025Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • A61K31/4523Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4535Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom, e.g. pizotifen
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00Medicinal preparations containing inorganic active ingredients
    • A61K33/24Heavy metals; Compounds thereof
    • A61K33/243Platinum; Compounds thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Inorganic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
ZA9604682A 1995-06-06 1996-06-05 Methods of inhibiting melanoma. ZA964682B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US08/466,673 US5843974A (en) 1995-06-06 1995-06-06 Methods of inhibiting melanoma using Benzothiophenes as cytotoxic agents per se

Publications (1)

Publication Number Publication Date
ZA964682B true ZA964682B (en) 1997-12-05

Family

ID=23852667

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA9604682A ZA964682B (en) 1995-06-06 1996-06-05 Methods of inhibiting melanoma.

Country Status (16)

Country Link
US (1) US5843974A (es)
EP (1) EP0747053A3 (es)
JP (1) JPH11507371A (es)
KR (1) KR19990022364A (es)
CN (1) CN1192141A (es)
AU (1) AU702716B2 (es)
CA (1) CA2223157A1 (es)
CZ (1) CZ383197A3 (es)
EA (1) EA000680B1 (es)
HU (1) HUP9901093A3 (es)
IL (1) IL118574A0 (es)
MX (1) MX9709466A (es)
NO (1) NO975580L (es)
PL (1) PL323924A1 (es)
WO (1) WO1996039135A1 (es)
ZA (1) ZA964682B (es)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6048847A (en) * 1997-09-30 2000-04-11 Dabur Research Foundation Use of betulinic acid and its derivatives for inhibiting cancer growth and a method of monitoring this
US6228850B1 (en) * 1997-09-30 2001-05-08 Dabur Research Foundation Antiangiogenic activity of betulinic acid and its derivatives
US6670345B1 (en) 1997-09-30 2003-12-30 Dabur Research Foundation Betulinic acid derivatives for inhabiting cancer growth and process for the manufacture of betulinic acid
EP1175433B1 (en) 1999-05-04 2005-08-03 Strakan International Limited Androgen glycosides and androgenic activity thereof
AU2005218759B2 (en) * 2004-02-27 2009-07-16 Antisense Pharma Gmbh Pharmaceutical composition
CA2560269A1 (en) * 2004-03-19 2005-09-29 The Penn State Research Foundation Combinatorial methods and compositions for treatment of melanoma
CA2882292C (en) * 2012-08-13 2023-10-17 The Rockefeller University Treatment and diagnosis of melanoma
CA2939120A1 (en) 2014-01-10 2015-07-16 Rgenix, Inc. Lxr agonists and uses thereof
US9758786B2 (en) 2016-02-09 2017-09-12 Autotelic, Llc Compositions and methods for treating pancreatic cancer
US11214536B2 (en) 2017-11-21 2022-01-04 Inspirna, Inc. Polymorphs and uses thereof
MX2022007164A (es) 2019-12-13 2022-09-12 Inspirna Inc Sales metálicas y usos de estas.

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4133814A (en) * 1975-10-28 1979-01-09 Eli Lilly And Company 2-Phenyl-3-aroylbenzothiophenes useful as antifertility agents
US4418068A (en) * 1981-04-03 1983-11-29 Eli Lilly And Company Antiestrogenic and antiandrugenic benzothiophenes
US4380635A (en) * 1981-04-03 1983-04-19 Eli Lilly And Company Synthesis of acylated benzothiophenes
US4656187A (en) * 1981-08-03 1987-04-07 Eli Lilly And Company Treatment of mammary cancer
US5075321A (en) * 1987-03-24 1991-12-24 University Of Pennsylvania Methods of treating diseases characterized by interactions of IgG-containing immune complexes with macrophage Fc receptors using antiestrogenic benzothiophenes
TW366342B (en) * 1992-07-28 1999-08-11 Lilly Co Eli The use of 2-phenyl-3-aroylbenzothiophenes in inhibiting bone loss
UA32427C2 (uk) * 1993-10-15 2000-12-15 Елі Ліллі Енд Компані Застосування бензотіофенів або їх фармацевтично прийнятних солей або сольватів для інгібування ангіогенезу і/або ангіогенних захворювань
HUT71237A (en) * 1993-10-15 1995-11-28 Lilly Co Eli Pharmaceutical compositions for treating resistant neoplasms containing 2-phenyl-3-aroil-benzotiophene derivatives and process for their preparation
US5457113A (en) * 1993-10-15 1995-10-10 Eli Lilly And Company Methods for inhibiting vascular smooth muscle cell proliferation and restinosis
US5476862A (en) * 1993-12-21 1995-12-19 Eli Lilly And Company Methods of increasing thrombomodulin expression
US5622975A (en) * 1995-06-01 1997-04-22 Eli Lilly And Company Methods for inhibiting vascular smooth muscle cell migration
US5726168A (en) * 1995-10-12 1998-03-10 Eli Lilly And Company Lipophilic benzothiophenes
US5780497A (en) * 1996-04-19 1998-07-14 American Home Products Corporation 2-phenyl-1- 4-(amino-1-yl-alk-1-ynyl)-benzyl!-1H-indol-5-ols as estrogenic agents

Also Published As

Publication number Publication date
KR19990022364A (ko) 1999-03-25
CN1192141A (zh) 1998-09-02
PL323924A1 (en) 1998-04-27
IL118574A0 (en) 1996-10-16
JPH11507371A (ja) 1999-06-29
CZ383197A3 (cs) 1998-07-15
EA199800015A1 (ru) 1998-06-25
EP0747053A3 (en) 1997-01-29
NO975580D0 (no) 1997-12-03
AU702716B2 (en) 1999-03-04
CA2223157A1 (en) 1996-12-12
WO1996039135A1 (en) 1996-12-12
HUP9901093A3 (en) 2000-02-28
AU6109096A (en) 1996-12-24
EA000680B1 (ru) 2000-02-28
NO975580L (no) 1997-12-03
EP0747053A2 (en) 1996-12-11
US5843974A (en) 1998-12-01
HUP9901093A2 (hu) 1999-10-28
MX9709466A (es) 1998-02-28

Similar Documents

Publication Publication Date Title
PL321759A1 (en) Novel thrombosin inhibitors
PL331900A1 (en) 1,4-heterocyclic inhibitors of metaloprotease
EP0835109A4 (en) PYRIDINONE-BASED THROMBIN INHIBITORS
PL331838A1 (en) 1,3-diheterocyclic inhibitors of metaloproteases
PL327569A1 (en) Promedications of thrombosin inhibitors
ZA961076B (en) Methods of inhibiting cell-cell adhesion.
ZA969221B (en) Indolealkyl derivatives of benzodioxanmethylamine.
ZA965922B (en) Preparation of N-substituted 3-hydroxypyrazoles.
ZA964682B (en) Methods of inhibiting melanoma.
GB2306848B (en) Hydrophone
IL122338A0 (en) Methods of inhibiting phagocytosis
GB2297021B (en) Bracelet
HU9601971D0 (en) Fastening plug
AU127304S (en) Case
ZA96897B (en) Methods of inhibiting effects of IL-6.
ZA967282B (en) Zwitterionic forms of trovafloxacin.
GB9510563D0 (en) Well inhibition
HK1016175A1 (en) Substituted phenyluracils
ZA963753B (en) Synthesis of benzoquinolinones.
SG64924A1 (en) Inhibiting photodecompostion of 3-substituted-2- oxindoles
GB9503380D0 (en) Substituted azo-dicarbonylo deriratives
GB9506678D0 (en) Substituted 6-azacholesten-3-ones
ZA979045B (en) Derivates of pentaerythrits.
HU9500363D0 (en) Personal alarm
ZA969226B (en) Protection of hand-portable objects.